Un recent job of the renowned Imperial College London examined the action of a hormone called Kisspeptin (and therefore known as the “kissing hormone”). The aim is to create highly effective drugs to treat sexual dysfunction in patients, both men and women, who suffer from low libido.
Kisspeptine drug: the study
A 2021 study he had already found out that kisspeptin is a neuromodulator that acts as a sort of “central hub” for sex-related hormone secretions. It plays an important role in the initiation of puberty and also affects physical processes such as the development of eggs and sperm, as well as mental phenomena such as libido and behavior patterns.
Imperial College has now confirmed this discovery about the natural hormone, and did so by studying both men and women with low libido.
The sting that's cool
Participants received kisspeptin injections and looked at pictures of attractive people. In men, the “mechanical reaction” to arousal was also tested.
The results of the study conducted by the endocrinologist Dr Alexander Comninos, published separately by genre in the journal JAMA Network Open (I link them to you here), show that kisspeptin injection increases sexual response in both sexes.
Quite a bit of good news
Considering that hypoactive sexual desire disorder (HSDD) it affects up to 10% of women and 8% of men worldwide, with serious psychological and social consequences for those who suffer from it, a drug like this could be very important.
Curiously, the research (which also features several patient testimonials) shows that participants treated with kisspeptin also feel more attractive.
“And without side effects,” the researchers point out. I am sure that many are eager to see the next stages of this research. Even those about others hormoneshowever, they are not bad.
